Brought to you by 
Domain Therapeutics launches Mavalon with €9mm Series A round from Medicxi
18 Oct 2016
Executive Summary
VC firm Medicxi invested €9mm ($9.9mm) to launch a new UK pharmaceutical company, Mavalon Therapeutics Ltd., formed to advance Domain Therapeutics SA's small-molecule G protein-coupled receptor (GPCR) pipeline in the area of Parkinson's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Domain Therapeutics launches Mavalon with €9mm Series A round from Medicxi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice